Drug intelligence / Profile preview

ENC-101-hPTG

Development stage
Preclinical
Lead developer
Encellin
Modality
Cell Therapies
Administration
Implant, Subcutaneous
01

Overview

ENC-101-hPTG is an investigational encapsulated cell therapy being developed by Encellin for the treatment of severe refractory hypoparathyroidism. The therapy utilizes Encellin's proprietary Encapsulated Cell Replacement Therapy (ENCRT) platform, which consists of a nanoporous, immunoprotective, and pro-angiogenic membrane pouch. This pouch is loaded with primary human parathyroid gland (PTG) cells. Once implanted subcutaneously, the device is designed to protect the allogeneic parathyroid cells from host immune rejection and fibrosis while allowing the free exchange of nutrients, calcium, and parathyroid hormone (PTH). By restoring physiological PTH secretion, ENC-101-hPTG aims to regulate systemic calcium homeostasis without requiring lifelong immunosuppression or daily hormone injections.

Other names
ENC 10x xPTGENC10x xPTGENC-10x xPTG
02

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)CaSR (Extracellular calcium-sensing receptor)

Beyond the preview

Go deeper on ENC-101-hPTG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENC-101-hPTG.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call